Literature DB >> 14982275

Metastatic insulinoma: case report and review of the literature.

Tuan-Huy Tran1, Ram D Pathak, Amelita L P Basa.   

Abstract

A 64-year-old nondiabetic woman presented with spells of lightheadedness and diaphoresis associated with lethargy and hunger of 2 weeks' duration. Physical examination was unremarkable; however, her fasting plasma glucose was 66 mg/dl, with concurrent plasma insulin of 171 microIU/ml (normal, 5-27 microIU/ml). Her C-peptide and pro-insulin levels were elevated, with negative insulin antibody and negative urinary sulfonylurea levels. Abdominal computed tomographic scan demonstrated a 5 x 4-cm mass in the tail of the pancreas and many liver metastases. She underwent resection of the pancreatic mass, radiofrequency ablation, and cauterization of hepatic lesions. Histology confirmed pancreatic insulinoma. Ten months later, she was free of hypoglycemic symptoms, with normal plasma insulin C-peptide and significantly decreased proinsulin levels. Insulinomas are rare, predominantly benign tumors. Surgery is the only curative treatment. Octreotide can be used to control hormone secretion and tumor growth. Other treatments include hepatic embolization, radiotherapy, chemotherapy, and liver transplantation.

Entities:  

Mesh:

Year:  2004        PMID: 14982275     DOI: 10.1097/01.SMJ.0000091035.18498.47

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  2 in total

Review 1.  Malignant insulinoma: spectrum of unusual clinical features.

Authors:  Boaz Hirshberg; Craig Cochran; Monica C Skarulis; Steven K Libutti; H Richard Alexander; Bradford J Wood; Richard Chang; David E Kleiner; Phillip Gorden
Journal:  Cancer       Date:  2005-07-15       Impact factor: 6.860

2.  Acanthosis nigricans in a patient with metastatic insulinoma post peptide receptor radionuclide therapy.

Authors:  Jenny S W Yun; Chris McCormack; Michelle Goh; Cherie Chiang
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2022-06-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.